

Progress of research on prodigiosin

Xinfeng Tan*, Xin Wang^a

State Key Laboratory of Biobased Material and Green Papermaking, School of Bioengineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China

* Corresponding author: Xinfeng Tan (Email: t1664294917@163.com), ^a1187279930@qq.com

Abstract: Prodigiosin is a natural red pigment derived primarily from secondary metabolites of microorganisms, especially *Serratia marcescens*. Prodigiosin has been proven to have antitumor, antibacterial, antimalaria, anti-insect, antialgae, and immunosuppressive activities, and is gaining increasing importance in the global market because of its great potential application value in clinical medicine development, environmental treatment, preparation of food additives, and so on. This paper reviews the progress of the research on prodigiosin.

Keywords: Prodigiosin; Secondary metabolite; Bioactivity.

1. Introduction

Prodigiosin is a red microbial pigment with a tripyrrole ring structure with the molecular formula $C_{20}H_{25}N_3O$ [1-3]. It is mainly produced by *Serratia marcescens* [4-5], *Pseudomonas*, actinomycetes and some marine bacteria [6-8]. Prodigiosin, which is red under acidic and neutral conditions and yellow under alkaline conditions [9-10], is a biologically active secondary metabolite with many medicinal uses and has important roles in antibacterial [13-14], algacidal, anticancer, antimalarial, anti-inflammatory [15-16], antidiabetic and immunomodulatory properties.

2. Biosynthesis of prodigiosin

As a result of the wide range of bioactivity of prodiginines, many studies on prodiginines biosynthesis have been reported in the past decades. Through a set of analysis which includes homology detection among enzymes, repressing the genes to identify its function, analysis of intermediate metabolites, and complementation experiments, the pathways and regulatory mechanisms for prodigiosin production in *S. marcescens* and *S. coelicolor* are now clear [17,18]. Two key intermediates, 2-methyl-3-n-aminopyrrole (MAP) and 4-methoxy-2,2'-bipyrrrole-5-carbaldehyde (MBC), are synthesized by bifurcated pathway.

In *S. marcescens* and *S. coelicolor*, the biosynthesis of MBC begins with the activation of L-proline as a thioester and is subsequently converted to the pyrrole ring A of prodigiosin. In the upcoming steps, C2 unit provided by malonyl CoA, C2N unit provided by serine, and methyl group provided by S-adenosylmethionine successively combine with pyrrole ring A to form MBC. In *S. marcescens*, MAP is formed in a three-step reaction from the initial precursor, 2-octenoyl CoA, which was formed by the combination of 2-octenal and pyruvate. Finally, MBC and MAP are condensed by enzyme to form prodigiosin.

In different bacteria species, the gene clusters involved in prodigiosin synthesis vary greatly. For example, the Pig cluster and the Red cluster are responsible for the biosynthesis of prodigiosin in *Serratia* sp. and *Streptomyces* sp., respectively [17,19]. Other clusters include Hap cluster from *H. chejuensis* and Tam cluster from *Pseudoalteromonas tunicata*. The Pig clusters of *S. marcescens* has a certain degree

of genomic modularization. The Pig B, Pig D, Pig E gene encodes the protein for biosynthesis of MAP, and Pig C is involved in the final step of condensation of MAP with MBC to form prodigiosin. The rest of the Pig cluster, containing Pig A and Pig F–Pig N, encodes proteins that are directly or indirectly involved in MBC biosynthesis.

It is worth noting that the synthesis pathway of MBC is highly conserved. All clusters have a specific set of genes that are homologous to each of the enzymes involved in the formation of MBC in *S. marcescens*, suggesting that MBC biosynthesis was a common pathway. However, the biosynthetic pathway of MAP is completely different. For instance, none of the proteins involved in MAP biosynthesis in *S. marcescens* had close homologs in the Red cluster. In addition, Pig C homologs were found in all clusters such as Red H, Hap C, Tam Q.

3. Bioactivity of prodigiosin

Increased attention on the red pigments and their derivatives is due to their inherent bioactivity against several strains of bacteria, algae, larva, and parasites [21,22]. They are also well-known for their higher immunomodulating capability and cytotoxicity against cancerous cells. Being a pigment, the prime activity expected from these molecules is their anti-oxidant capability.

3.1. Antimicrobial activity

In antimicrobial approaches, numerous pathogens have been tested and have shown growth inhibition or even programmed cell death characteristics. Research regarding the interaction between microbiota and an amphibian host implies assistance from *S. marcescens* against *Batrachochytrium dendrobatidis* via production of prodigiosin. According to the application of antifungal function, PG has been used for preventing red tide [25–26]. Collecting the known detailed mechanisms, the induction of ROS and inhibition of microcystin production (a group of small toxic cyclin peptides believed to respond to nutrient stress) are major reactions and cause the leakage of the plasma membrane. Interestingly, PG is also an antioxidant for which the potency of antioxidation activity is at least ten-times higher than that of α -tocopherol [28,29]. How PG triggers oxidative stress and prevents ROS scavenging is still

unknown. While combined with N-myristoyltyrosine, the IC50 of PG against *Corynebacterium glutamicum* can drop from 1.6 µg/mL to 5 ng/mL. Furthermore, PG induced the cell apoptosis of *Bombyx mori* nucleopolyhedrovirus infected silkworm cells but not normal cells in the same species, indicating that PG possesses antiviral activities. Taken together, PG is suitable for food additives owing to antimicrobial activities and its bright-red color.

3.2. Antimalarial activity

Malaria is a mosquito-borne infectious disease, which is transmitted by *Plasmodium* through the bite of *Anopheles* mosquitoes. Gerber et al. for the first time reported the antimalarial activity of prodiginines. They found methylcyclodecylprodigiosin extended the lifespan of mice infected with *Plasmodium berghei*, but other prodiginines either had no therapeutic effect or showed toxicity to mice. Another study reported that cycloprodigiosin was an effective anti-malarial drug against *P. berghei*, with an IC50 of 11 nM. Its performance in anti-malarial test was even much better than the traditional antimalarial drugs, chloroquine, and its derivatives. In addition, four new prodiginine derivatives were synthesized and tested against four different sources of *P. falciparum*, and only isoheptylprodigiosin and 2-methyl-3-butyl prodigiosin exhibited strong inhibition activities.

Interestingly, prodiginines were also proven to be effective mosquitoicides, which have considerable potential in the biological control of mosquito larval populations by killing intermediate carriers and blocking the transmission route of *Plasmodium* sp. The research found that prodigiosin showed strong inhibition against early stage II of *Aedes aegypti* and *Anopheles stephensi* with a LC50 of 14 ± 1.2 µg/mL and 19.7 ± 1.12 µg/mL, respectively. The prodigiosin could inhibit H⁺-V-ATPase to decrease the pH in midgut and cecum of the fourth-stage larvae of *A. aegypti*. A drop in pH leads to reduced nutrient uptake and death of *A. aegypti* larvae. Besides, prodigiosin showed a good performance against mosquito larvae by the combining with other compounds or bacteria extracts. For example, prodigiosin could work as a photoprotectant to enhance the killing effect of *Bacillus thuringiensis* BtSV2 on *A. stephensi* stage IV larvae, and *S. marcescens* could inhibit *A. aegypti* by producing a combination of prodigiosin and other secondary metabolites like serratomolides.

3.3. Immunosuppressive activity

The inhibition of the cell cycle is a unique property of prodigiosin, which is found and established at non-apoptotic doses, like an immunosuppressant. Prodigiosin has been found to reduce graft versus host disease (GvHD). For this, no remarkable sign of toxicity was found in mouse models. In addition to that, prodigiosin also has another important effect, which is the delay in the progression of autoimmune diabetes. Literature reported that prevention of GvHD and collagen-induced arthritis (which were very common) was successfully carried out in mouse model. Undecylprodigiosin, metacycloprodigiosin, and cycloprodigiosin all are different forms of prodigiosin-inhibited proliferation of T cells. Yet, various levels of in vivo toxicity were reported.

4. Conclusion

So prodigiosin was found as a significant pigment, which belongs to a family of natural red dye. It was found in various types of bacteria, but first, it was isolated from *Serratia*

marcescens and also had unique pyrrolyl pyrromethane structures. It has several functions such as anti-fungal, anti-bacterial, anti-malarial, and anti-cancer activities and catalyzes the progression of apoptosis which means programmed cell death in different cancer cell lines.

To gain an in-depth understanding of the biosynthetic pathway of prodiginines, finding key factors that stimulate compound production is necessary. Finally, it is the question of compound stability. The prodiginines are very easy to be photolyzed, which largely limits their applications. Therefore, more efforts should be made to increase the chemical stability of prodiginines without losing their bioactivity.

References

- [1] Zang, C.-Z.; Yeh, C.-W.; Chang, W.-F.; Lin, C.-C.; Kan, S.-C.; Shieh, C.-J.; Liu, Y.-C. Identification and enhanced production of prodigiosin isoform pigment from *Serratia marcescens* N10612. *J. Taiwan Inst. Chem. Eng.* 2014, 45, 1133–1139.
- [2] Zhou, W.; Li, J.; Chen, J.; Liu, X.; Xiang, T.; Zhang, L.; Wan, Y. The red pigment prodigiosin is not an essential virulence factor in entomopathogenic *Serratia marcescens*. *J. Invertebr. Pathol.* 2016, 136, 92–94.
- [3] El-Bialy, H.A.; El-Nour, S.A.A. Physical and chemical stress on *Serratia marcescens* and studies on prodigiosin pigment production. *Ann. Microbiol.* 2014, 65, 59–68.
- [4] Bennett, J.; Bentley, R. Seeing red: The story of prodigiosin. *Adv. Clin. Chem.* 2000, 47, 1–32.
- [5] Zarei, M.; Aminzadeh, S.; Zolgharnein, H.; Safahieh, A.; Ghoroghi, A.; Motallebi, A.; Daliri, M.; Lotfi, A.S. *Serratia marcescens* B4A chitinase product optimization using Taguchi approach. *Iran J. Biotechnol.* 2010, 8, 252–262.
- [6] Sevcikova, B.; Kormanec, J. Differential production of two antibiotics of *Streptomyces coelicolor* A3(2), actinorhodin and undecylprodigiosin, upon salt stress conditions. *Arch. Microbiol.* 2004, 181, 384–389.
- [7] Rossa, C.; White, J.; Kuiper, A.; Postma, P.; Bibb, M.; de Mattos, M.T. Carbon Flux Distribution in Antibiotic-Producing Chemostat Cultures of *Streptomyces lividans*. *Metab. Eng.* 2002, 4, 138–150.
- [8] Stankovic, N.; Senerovic, L.; Ilic-Tomic, T.; Vasiljevic, B.; Nikodinovic-Runic, J. Properties and applications of undecylprodigiosin and other bacterial prodigiosins. *Appl. Microbiol. Biotechnol.* 2014, 98, 3841–3858.
- [9] Andreyeva, I.N.; Ogorodnikova, T.I. Pigmentation of *Serratia marcescens* and spectral properties of prodigiosin. *Microbiology* 2015, 84, 28–33.
- [10] Drink, E.; Dugourd, P.; Dumont, E.; Aronsson, N.; Antoine, R.; Loison, C. Optical properties of prodigiosin and obatoclax: Action spectroscopy and theoretical calculations. *Phys. Chem. Chem. Phys.* 2015, 17, 25946–25955.
- [11] Williamson, N.R.; Fineran, P.C.; Gristwood, T.; Chawrai, S.R.; Leeper, F.J.; Salmond, G.P.C. Anticancer and immunosuppressive properties of bacterial prodiginines. *Future Microbiol.* 2007, 2, 605–618.
- [12] Lazaro, J.E.H.; Nitchou, J.; Predicala, R.Z.; Mangalindan, G.C.; Nesslany, F.; Marzin, D.; Concepcion, G.P.; Diquet, B. Heptyl prodigiosin, a bacterial metabolite, is antimalarial in vivo and non-mutagenic in vitro. *J. Nat. Toxins* 2002, 11, 367–377. [PubMed]
- [13] Nakashima, T.; Kurachi, M.; Kato, Y.; Yamaguchi, K.; Oda, T. Characterization of Bacterium Isolated from the Sediment at Coastal Area of Omura Bay in Japan and Several Biological Activities of Pigment Produced by This Isolate. *Microbiol. Immunol.* 2005, 49, 407–415.

- [14] Nakashima, T.; Kato, Y.; Yamaguchi, K.; Oda, T. Evaluation of the anti-Trichophyton activity of a prodigiosin analogue produced by gamma-proteobacterium, using stratum corneum epidermis of the Yucatan micropig. *J. Infect. Chemother.* 2005, 11, 123–128.
- [15] Azambuja, P.; Feder, D.; Garcia, E. Isolation of *Serratia marcescens* in the midgut of *Rhodnius prolixus*: Impact on the establishment of the parasite *Trypanosoma cruzi* in the vector. *Exp. Parasitol.* 2004, 107, 89–96.
- [16] Genes, C.; Baquero, E.; Echeverri, F.; Maya, J.D.; Triana, O. Mitochondrial dysfunction in *Trypanosoma cruzi*: The role of *Serratia marcescens* prodigiosin in the alternative treatment of Chagas disease. *Parasites Vectors* 2011, 4, 66–68.
- [17] Harris AKP, Williamson NR, Slater H, Cox A, Abbasi S, Foulds I, et al. The *Serratia* gene cluster encoding biosynthesis of the red antibiotic, prodigiosin, shows species and strain-dependent genome context variation. *Microbiology.* 2004;150:3547–60.
- [18] Williamson NR, Simonsen HT, Ahmed RA, Goldet G, Slater H, Woodley L, et al. Biosynthesis of the red antibiotic, prodigiosin, in *Serratia*: identification of a novel 2-methyl-3-n-amylopyrrole (MAP) assembly pathway, definition of the terminal condensing enzyme, and implications for undecylprodigiosin biosynthesis in *Streptomyces*. *Mol Microbiol.* 2005;56:971–89.
- [19] Cerdeño AM, Bibb MJ, Challis GL. Analysis of the prodiginine biosynthesis gene cluster of *Streptomyces coelicolor* A3(2): new mechanisms for chain initiation and termination in modular multienzymes. *Chem Biol.* 2001;8:817–29.
- [20] Burke C, Thomas T, Egan S, Kjelleberg S. The use of functional genomics for the identification of a gene cluster encoding for the biosynthesis of an antifungal tambjamine in the marine bacterium *Pseudoalteromonas tunicata*. *Environ Microbiol.* 2007;9:814–8.
- [21] Ramesh C, Vinithkumar NV, Kirubakaran R, Venil CK, Dufossé L (2020) Applications of prodigiosin extracted from marine red pigmented bacteria *Zooshikella* sp. and *Actinomyces streptomyces* sp. *Microorganisms* 8(4):556.
- [22] Balasubramaniam B, Alexandri R, Darjily DR (2019) Exploration of the optimized parameters for bioactive prodigiosin mass production and its biomedical applications in vitro as well as in silico. *Biocatal Agric Biotechnol* 22:101385.
- [23] Yip C-H, Yarkoni O, Ajioka J, Wan K-L, Nathan S (2019) Recent advancements in high-level synthesis of the promising clinical drug, prodigiosin. *Appl Microbiol Biotechnol* 103(4):1667–1680.
- [24] Madison, J.D. et al. (2019) *Serratia marcescens* shapes cutaneous bacterial communities and influences survival of an amphibian host. *Proc. Biol. Sci.* 286, 20191833
- [25] Nakashima, T. et al. (2006) Producing mechanism of an algicidal compound against red tide phytoplankton in a marine bacterium gamma-proteobacterium. *Appl. Microbiol. Biotechnol.* 73, 684–690
- [26] Wei, J. et al. (2020) Simultaneous *Microcystis* algicidal and microcystin synthesis inhibition by a red pigment prodigiosin. *Environ. Pollut.* 256, 113444
- [27] Pimentel, J.S. and Giani, A. (2014) Microcystin production and regulation under nutrient stress conditions in toxic *microcystis* strains. *Appl. Environ. Microbiol.* 80, 5836–5843
- [28] Arivizhivendhan, K.V. et al. (2018) Antioxidant and antimicrobial activity of bioactive prodigiosin produced from *Serratia marcescens* using agricultural waste as a substrate. *J. Food Sci. Technol.* 55, 2661–2670
- [29] Yildiztekin, F. et al. (2016) Antioxidant, anticholinesterase and tyrosinase inhibition activities, and fatty acids of *Crocus mathewii* – a forgotten endemic angiosperm of Turkey. *Pharm. Biol.* 54, 1557–1563
- [30] Hage-Hulsmann, J. et al. (2018) Natural biocide cocktails: combinatorial antibiotic effects of prodigiosin and biosurfactants. *PLoS One* 13, e0200940
- [31] Zhou, W. et al. (2016) Antiviral activity and specific modes of action of bacterial prodigiosin against *Bombyx mori* nucleopolyhedrovirus in vitro. *Appl. Microbiol. Biotechnol.* 100, 3979–3988
- [32] Phillips M, Burrows J, Manyando C, van Huijsduijnen R, Van Voorhis W, Wells T (2017) *Malaria*. *Nat Rev Dis Primers* 3:17050.
- [33] Gerber NN (1975) A new prodiginine (prodigiosin-like) pigment from *Streptomyces*. Antimalarial activity of several prodiginines. *J Antibiot* 28(3):194–9.
- [34] Kim HS, Hayashi M, Shibata Y, Wataya Y, Mitamura T, Horii T, Kawauchi K, Hirata H, Tsuboi S, Moriyama Y (1999) Cycloprodigiosin hydrochloride obtained from *Pseudoalteromonas denitrificans* is a potent antimalarial agent. *Biol Pharm Bull* 22(5):532–534.
- [35] Kancharla P, Li Y, Yeluguri M, Dodean RA, Reynolds KA, Kelly JX (2021) Total synthesis and antimalarial activity of 2-(p-Hydroxybenzyl)-prodigiosins, isoheptylprodigiosin, and geometric isomers of tambjamine MYP1 isolated from marine bacteria. *J Med Chem* 64(12):8739–8754.
- [36] Suryawanshi RK, Patil CD, Borase HP, Narkhede CP, Salunke BK, Patil SV (2015) Mosquito larvicidal and pupaecidal potential of prodigiosin from *Serratia marcescens* and understanding its mechanism of action. *Pestic Biochem Physiol* 123:49–55.
- [37] Meng-xi LI, Hui-bin H, Jie-yun L, Jing-xiao CAO, Zhen-wang Z (2021) Antibacterial performance of a *Streptomyces spectabilis* strain producing metacycloprodigiosin. *Curr Microbiol* 78(7):2569–2576.
- [38] Heu K, Romoli O, Schönbeck JC, Ajenoe R, Epelboin Y, Kircher V, Houël E, Estevez Y, Gendrin M (2021) The effect of secondary metabolites produced by *Serratia marcescens* on *Aedes aegypti* and its microbiota. *Front Microbiol* 12:645701.
- [39] Han SB, Park SH, Jeon YJ, Kim YK, Kim HM, Yang KH (2001) Prodigiosin blocks T cell activation by inhibiting interleukin-2R α expression and delays progression of autoimmune diabetes and collagen-induced arthritis. *J Pharmacol Exp Ther* 299(2):415–425.
- [40] Han SB, Park SH, Jeon YJ, Kim YK, Kim HM, Yang KH (2001) Prodigiosin blocks T cell activation by inhibiting interleukin-2R α expression and delays progression of autoimmune diabetes and collagen-induced arthritis. *J Pharmacol Exp Ther* 299(2):415–425.
- [41] Tomás P, Ricardo E, Montaner B (2003) Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. *Histol Histopathol* 18(2):379–385.